CCR5 and viral infectious disease: We observed 85–90% inhibition in D24 viral infection in the presence of two different anti-human CD4 monoclonal antibodies (generated in-house), soluble CD4, small molecule inhibitors against the coreceptors (TAK-779 and JM-2987 for CCR5 and CXCR4, respectively) or monoclonal antibodies to the coreceptors.